8-K current report · filed Sep 4, 2026

Intellia Therapeutics, Inc. (NTLA) 8-K Current Report: September 4, 2026

Item 1.01Item 2.03Item EX-99.1Item 7.01NTLA overview

Short answer

Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on September 4, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). $400M five-year senior secured facility, with $75M drawn at closing for working capital and general corporate purposes.

Intellia Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $400M five-year senior secured facility, with $75M drawn at closing for working capital and general corporate purposes
  • Additional borrowing tied to FDA BLA approval, lonvo-z revenue targets, and a $30M equity fundraising target
  • Loans mature September 4, 2031, with monthly interest at one-month SOFR plus 6.15%, subject to a 3.00% floor
  • First-priority collateral includes substantially all company assets, including intellectual property
  • $50M minimum liquidity covenant before lonvo-z BLA approval, alongside restrictions on debt, acquisitions, licensing, and asset sales

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 links to Item 1.01, indicating a newly created direct financial obligation under a material agreement
  • Investor impact depends on Item 1.01 terms, including obligation size, payment structure, interest, maturity and purpose

Item 7.01 · Regulation FD Disclosure

  • Press release announces non-dilutive debt facility with OrbiMed, providing up to $400 million of potential funding
  • Additional $100 million remains subject to mutual agreement between Intellia and lenders
  • Proceeds expected to support strategy and development of lonvoguran ziclumeran for hereditary angioedema
  • Further draws depend on regulatory, revenue and equity-financing milestones, creating execution risk

Item EX-99.1 · Exhibit EX-99.1

  • $75 million funded upfront under a $400 million non-dilutive senior secured term loan
  • Additional $225 million available through five milestone-based tranches, primarily tied to lonvo-z
  • Potential $100 million more available by mutual agreement during the five-year term
  • Financing supports lonvo-z launch preparations and nex-z development without immediate equity dilution
  • Senior secured debt adds repayment obligations, restrictive covenants, security interests, and default risk

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Intellia Therapeutics, Inc. 8-K filings

Get the next NTLA 8-K as it lands

Follow NTLA for push alerts, or ask the research agent what this filing means.